Related Experiment Video
Updated: Jun 5, 2025
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney disease
Maha Abd El Moneem Elfedawy1, Samia Abd El Sadek Elsebai1, Hend Mohamed Tawfik1
1Department of Internal Medicine, Faculty of Medicine, Al-Azher University (for girls), Egypt.
Insights
Adropin levels were significantly lower in chronic kidney disease (CKD) patients with cardiovascular disease (CVD) history. This study suggests adropin may serve as a potential biomarker for predicting CVD onset in CKD patients.
Area of Science:
- Endocrinology
- Nephrology
- Cardiology
Background:
- Chronic kidney disease (CKD) poses a significant global health burden, associated with high mortality and morbidity, particularly from cardiovascular disease (CVD).
- Adropin, a hormone encoded by the energy homeostasis-associated (Enho) gene, has emerged as a potential factor in metabolic and cardiovascular health.
Purpose of the Study:
- To investigate the potential of adropin as a diagnostic biomarker for CVD in patients diagnosed with CKD.
- To evaluate the relationship between adropin levels and the presence of CVD in a CKD cohort.
Main Methods:
- A prospective study involving 60 CKD patients and 30 healthy controls.
- CKD patients were stratified into those with (Group B) and without (Group A) a history of CVD.
- Serum adropin, lipids, Hs-CRP levels were measured using ELISA, and echocardiography was performed. ROC curve analysis determined diagnostic cut-off points.
Main Results:
- Adropin levels were significantly decreased in CKD patients with CVD history (Group B) compared to Group A and controls.
- Conversely, serum lipids and Hs-CRP were elevated in Group B compared to Group A and controls.
- ROC analysis indicated adropin's utility in discriminating between patients with and without CVD history, with varying sensitivity and specificity.
Conclusions:
- Adropin may serve as a valuable predictive biomarker for the development of CVD in patients with CKD.
- Adropin shows potential as a novel blood marker for assessing cardiac function, including systolic function and potentially Spontaneous Coronary Artery Dissection (SCAD).
Background:
Chronic kidney disease (CKD) is a chief worldwide health concern that has a substantial financial impact on health systems, high rates of mortality and morbidity as well as cardiovascular disease (CVD) is a major cause of mortality in this population. Adropin is a unique hormone encoded by the energy homeostasis-associated (Enho) gene.
Aim Of The Work:
We aimed to explore the efficacy of adropin as a diagnostic candidate biomarker for CVD in patients with CKD.
Methods:
This is prospective study was carried out on 60 patients (Pt) with CKD and 30 age and sex matched healthy control subjects. CKD Pt were classified according to the history of CVD into two groups: Group A, Pt without history (n = 32) and Group B, Pt with history (n = 28). Serum adropin, lipids and Hs-CRP were measured by ELISA kit. Echocardiography was also investigated. Receiver operator characteristic curve (ROC) was used to determine cut-off points of adropin. Negative predict value (NPV), negative predict value (NPV) and area under curve were detected.
Results:
There were abnormal ECGs in 78.6 % of CKD patients. Adropin was significantly decreased in Group B than Group A and control group. On the other hand, serum lipids and Hs-CRP were significantly increased in Group B than Group A and control group. ROC analysis revealed that serum adropin could be used to discriminate between patients with and without CVD history at a cutoff level of > 304 with 46.4 % sensitivity and 84.4 % specificity, 74.8 % PPV, 61.2 % NPV and AUC = 0.57. Moreover, between Group A and control at a cutoff level of < 410, with 93.8 % sensitivity, 86.7 % specificity, 87.6 % PPV and 93.3 % NPV and AUC = 0.97 as well as between Group B and control group at a cutoff level of < 416, with 57.1 % sensitivity, 83.3 % specificity, 77.4 % PPV and 66 % NPV and AUC = 0.65.
Conclusion:
Particularly in CKD patients, adropin may be a useful biomarker for predicting the onset of CVD. Adropin may represent a novel and useful blood marker for assessing systolic function and Spontaneous coronary artery dissection (SCAD).
More Related Videos
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:22Heart Failure Drugs: Diuretics
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System